Arlington Dermatology

Rolling Meadows, Illinois 60008-3811

3 studies enrolling now · 36 studies all time

What they study most

Acne Vulgaris, Actinic Keratosis, Atopic Dermatitis, Dermatitis, Atopic, Hand Eczema, Moderate Psoriasis, Plaque Psoriasis, Psoriasis, Psoriasis (PsO), Severe Psoriasis

Studies at this site

• A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis — Recruiting now
• Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities — Recruiting now
• Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp — Recruiting now
• A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis — Running, not enrolling
• A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — Running, not enrolling
• A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) — Running, not enrolling
• A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis — Running, not enrolling
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants — Running, not enrolling
• A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) — Running, not enrolling
• A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis — Running, not enrolling
• A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis — Completed
• A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis — Completed
• A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis — Completed
• Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis — Running, not enrolling
• A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis — Completed
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment — Completed
• Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis — Completed
• This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD) — Completed
• A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis — Completed
• Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis — Status unconfirmed
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis — Completed
• A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) — Stopped early
• A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis — Stopped early
• Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 — Withdrawn before enrolling
• A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis — Stopped early
• A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis — Completed
• Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis — Completed
• A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris — Completed
• A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis — Stopped early
• A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) — Completed
• A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis — Stopped early
• A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis — Completed